Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palivizumab Prophylactic Efficacy in RSV Challenge Study
NCT04540627Phase 1Completed
- Sponsor
- mAbxience
- Start
- Jul 2020
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing Palivizumab with Placebo (2 arms). Primary endpoints: Mean Serum Concentrations (Cmax) for Open-label Palivizumab at Day 12, Area Under the Viral Load-time Curve (VL-AUC) as Determined by qRT-PCR and 1 more. Started Jul 2020; status: completed.
02
Drugs
palivizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04540627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540627.